Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE2
A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab
- Status
- COMPLETED
- Phase
- PHASE3
Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)
- Status
- TERMINATED
- Phase
- PHASE2
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- COMPLETED
- Phase
- PHASE2
Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies
- Status
- COMPLETED
- Phase
- N/A
Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL
- Status
- UNKNOWN
- Phase
- PHASE3
Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)
- Status
- UNKNOWN
- Phase
- PHASE1
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2